Oncolix has dosed 3 of the planned 18 patients in the Phase I trial.
The SEC filings clearly state that the company is finalizing contract manufacturing for additional supplies of Prolanta before proceeding to dose the remaining 15 patients. That is the reason there is no news on the trial right now.
Since you seem new to this, Phase I trials are for safety and dosing, not efficacy, and seventy-five percent (75%) of drugs that make it to Phase I move past Phase I.
The Phase I trial for Prolanta is barely underway, much less a failure, and, based on past history and ODD designation, the smart money says Prolanta moves at least past Phase I.
Please back up your future assertions with facts or, at a minimum, qualify your statements with everyone's favorite, "IMO".